12/01/2017

Cutting-Edge Research in Germany's Far West

New cancer research findings need to reach patients as quickly as possible. It was to achieve this aim that the DKFZ joined forces with research institutes and clinics at eight locations across…

04/01/2017

Interview with Michael Baumann: “It won’t work without collaborative partnerships”

Prof. Michael Baumann has been Scientific Director of the German Cancer Research Center (DKFZ) and Spokesman for the German Cancer Consortium since November 1. Before that, he worked in Dresden for 20…

19/12/2016

DKTK Heidelberg: Kidnapped enhancer activates cancer gene

The DNA of cancer cells is different from healthy cells. Often, genes or entire gene regions are deleted or duplicated. Due to such structural mutations, cancer-releasing genes can enter the vicinity…

01/12/2016

€2.5 million for developing a novel cancer immunotherapy

Scientists from the German Cancer Consortium (DKTK) at Tübingen University Hospital have developed a promising bispecific antibody for use in immunotherapy of prostate cancer and so-called squamous…

01/12/2016

Essen Physicians Receive Prize for Best Studies on Carcinogenesis and Cancer Treatment

Two scientists of the German Cancer Consortium (DKTK) have received the highest award by the Oncology in Internal Medicine Working Group (AIO) of the German Cancer Society. The physicians Wilfried…

24/11/2016

Prof. Martin Schuler joins the board of the Oncology in Internal Medicine Working Group (AIO) within the German Cancer Society

In November, Prof. Martin Schuler, Director of Internal Medicine (tumor research) and spokesman for the Essen/Düsseldorf partner location of the German Cancer Consortium (DKTK), was voted onto the…

17/11/2016

Dr Stefan Kaufmann MP visits German Cancer Research Center

08/11/2016

DKTK Berlin: Boost for cancer therapies with tumors grown in petri-dish

2.6 Million Euros for the Charité Berlin Cancer can be caused by a variety of genetic mutations. One challenge medicine faces is finding tailor-made treatment for each patient based on their…

31/10/2016

DKTK Retreat 2016: The start of a new research period

Featuring researchers deep in conversation, pina coladas and a band in pilots’ uniforms, the annual retreat of the German Cancer Consortium (DKTK) celebrated the results of an extremely positive…

20/10/2016

Gene fusion opens up treatment possibilities for aggressive brain cancer

(DKTK Heidelberg with DKTK Freiburg, Essen/Düsseldorf) Glioblastoma, an extremely aggressive type of brain cancer, is still mostly untreatable in children. Scientists from the German Cancer…

26/09/2016

Michael Baumann, spokesperson of DKTK Dresden, will be the new scientific director of the German Cancer Research Center

The DKTK steering committee has unanimously elected Prof. Michael Baumann, the new scientific director of the German Cancer Research Center (DKFZ), as the new spokesperson of DKTK as of November 1,…

15/09/2016

DKTK Freiburg: Expertise gathered under one roof

The Center for Chronic Immunodeficiency and the Comprehensive Cancer Center Freiburg, a DKTK partner, have moved into the new Center for Translational Cell Research.

29/08/2016

DKTK Frankfurt/Mainz: Simone Fulda joins DFG’s Senate Commission

Professor Simone Fulda, deputy spokesperson of the German Cancer Consortium (DKTK) site in Frankfurt/Mainz, has been appointed by the Senate of the German Research Foundation (DFG), to serve on the…

29/08/2016

DKTK Dresden: CRISPR/Cas9 technology to inactivate cancer mutations

As for many other biomedical and biotechnology disciplines, the genome scissor “CRISPR/Cas9” also opens up completely new possibilities for cancer research. Scientists of the National Center for Tumor…

28/07/2016

DKTK Berlin and Heidelberg: New Biomarker for cancer immunotherapy?

The Ligand PD-L1 is one of the most important targets for cancer immunotherapy with checkpoint inhibitors. But not all tumors have sufficient quantities of PD-L1 ligands on their surface. Scientists…

03/07/2016

DKTK Freiburg: How different are tumor blood vessels?

Malignant tumors rapidly infiltrate neighboring normal tissue. To maintain their aggressive growth they form new blood vessels – this process is called neoangiogenesis and leads to abnormal vascular…

19/06/2016

DKTK München: Scientists discover mechanism of thalidomide

In the 1950s, thalidomide (Contergan) was prescribed as a sedative drug to pregnant women, resulting in a great number of infants with serious malformations. Up to now, the reasons for these…

15/06/2016

Pinpointing risk indicators

Together with researchers from the Ludwig Maximilians University (LMU) and the Helmholtz Zentrum München DKTK researchers from partner site München have developed a novel method that allows them to…

08/06/2016

DKTK Munich: Putting a brake on leukemia cells

Cancer cells need a lot of energy in order to be able to divide without limits. Researchers from the German Cancer Consortium (DKTK) at Munich University Hospital (LMU) have now discovered how…

31/05/2016

DKTK Essen/Düsseldorf: New treatment resistance mechanism in malignant melanoma

Press release of the University Hospital Essen Cancer treatment is improving even for advanced tumours, thanks to modern therapy. However, sooner or later, many patients develop resistance and the…